Skip to content

Advertisement

EJNMMI Research
EJNMMI Research Cover Image
  • Original research
  • Open Access

Prognostic value of simultaneous 18F-FDG PET/MRI using a combination of metabolo-volumetric parameters and apparent diffusion coefficient in treated head and neck cancer

EJNMMI Research20188:2

https://doi.org/10.1186/s13550-018-0357-9

©  The Author(s). 2018

  • Received: 19 October 2017
  • Accepted: 4 January 2018
  • Published:

Abstract

Background

The aim of this study was to determine the usefulness of combined positron emission tomography (PET)/magnetic resonance imaging (MRI) parameters provided by simultaneous 18F-fluorodeoxyglucose (FDG) PET/MRI for the prediction of treatment failure in surgically resected head and neck cancer. We hypothesized that PET parameters corrected by tumor cellularity (combined PET/MRI parameters) could predict the prognosis. On regional PET, maximum standardized uptake value (SUVmax) was measured as metabolic parameters. In addition, metabolic tumor volume (MTV) and total lesion glycolysis (TLG) were checked as metabolo-volumetric parameters. Mean apparent diffusion coefficient (ADCmean) of tumor was evaluated as the MRI parameter on the ADC map. Ratios between metabolic/metabolo-volumetric parameters and ADC were calculated as combined PET/MRI parameters. PET, MRI, and combined PET/MRI parameters were compared with clinicopathologic parameters in terms of treatment failure.

Results

Seventy-two patients (mean age = 55.9 ± 14.6 year, M: F = 45: 27) who underwent simultaneous 18F-FDG PET/MRI before head and neck cancer surgery were retrospectively enrolled. Twenty-two patients (30.6%) showed tumor treatment failure after head and neck cancer surgery (mean treatment failure = 13.0 ± 7.0 months). In the univariate analysis, MTV (P = 0.044) and ratios between metabolo-volumetric parameters and ADC (MTV/ADCmean, P = 0.022; TLG/ADCmean, P = 0.044) demonstrated significance among 18F-FDG PET/MRI parameters. Lymphatic invasion (P = 0.044) and perineural invasion (P = 0.046) revealed significance among clinicopathologic parameters. In the multivariate analysis, MTV (P = 0.026), MTV/ADCmean (P = 0.011), and TLG/ADCmean (P = 0.002) with lymphatic invasion (P = 0.026, 0.026, and 0.044, respectively) showed significance.

Conclusions

Combined PET/MRI parameters (PET metabolo-volumetric parameters corrected by tumor cellularity) could be effective predictors of tumor treatment failure after head and neck cancer surgery in addition to MTV and clinicopathologic parameter.

Keywords

  • Head and neck cancer
  • Integrated PET/MRI
  • Metabolic tumor volume
  • Total lesion glycolysis
  • Apparent diffusion coefficient

Background

Head and neck cancer involves many structures, including the nasal cavity, oral cavity, tongue, pharynx, larynx, and salivary glands, and the 5-year survival rate is about 65% [1]. 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) is widely used in current clinical practice for cancers. Regarding head and neck cancer, 18F-FDG PET/CT is recommended in diagnosis, staging, and recurrence detection [2]. Furthermore, 18F-FDG PET/CT has been reported to be effective in predicting head and neck cancer recurrence using quantitative parameters [3].

Simultaneous PET/magnetic resonance imaging (MRI) is a recently developed technology that is expected to be a better imaging modality than each modality alone due to the complementary information of each modality [4, 5]. In addition, simultaneous PET/MRI is expected to be more valuable than PET/CT because it involves less radiation exposure and offers better soft-tissue contrast resolution [6]. In head and neck cancer, MRI has an important role due to its excellent soft-tissue contrast, which provides anatomy of small structures in detail [7]. A previous study reported that simultaneous PET/MRI is feasible for the staging of head and neck cancer and the discordant result of PET and MRI might have a synergistic effect for accurate staging [8].

The main advantage of simultaneous PET/MRI is that several functional imaging types can be performed by MRI [9]. Among them, diffusion-weighted imaging (DWI), which enables the assessment of the random (Brownian) motion of water molecules without the injection of contrast materials or radiotracers, has been studied [10]. DWI can be quantified by the apparent diffusion coefficient (ADC), which reflects the cellularity of tumors [11]. In reference to head and neck cancer, ADC has been shown to be effective in diagnosis, staging, and therapeutic effect evaluation [12, 13]. In addition, ADC could be useful for predicting treatment response in head and neck cancer [14]. However, DWI using ADC has yet to be transferred to the clinical domain.

We hypothesized that PET parameters of simultaneous 18F-FDG PET/MRI could be more accurately characterized to reflect the aggressiveness of tumors by correcting tumor cellularity utilizing ADC in surgically resected head and neck cancer. We evaluated prognostic value of metabolic and metabolo-volumetric parameters of PET, ADC of MRI, and combined PET/MRI parameters in addition to several clinicopathologic parameters and compared them.

Methods

Patients

From March 2013 to December 2015, 128 patients underwent simultaneous 18F-FDG PET/MRI as a preoperative workup for head and neck cancer in our institution. Among them, patients who met the following inclusion criteria were retrospectively enrolled in this study: (1) underwent simultaneous 18F-FDG PET/MRI less than 2 months before surgery, (2) no evidence of distant metastasis during preoperative workup, and (3) follow-up more than 12 months after surgery in case of no treatment failure. Patients who performed initial treatment as concurrent chemoradiation therapy (CCRT) were excluded. Patients were routinely checked using laryngoscopy and imaging studies, such as ultrasonography, CT, or MRI, every 3–4 months in the first year after surgery and every 6 months thereafter. Additional imaging studies were performed when serum carcinoembryonic antigen (CEA) (checked at routine checkups at 3–4 months intervals; threshold of 5 ng/ml) was increased, or other suspicious symptoms or signs were presented. Treatment failure was mainly confirmed by histopathology when recurrence or metastasis was suspected during follow-up of laryngoscopy and imaging studies. When the hisopathologic confirmation was not feasible, radiologic confirmation was made based on mutual decision by radiologists and oncologists. The study design and waive of informed consents were approved by the Institutional Review Board (IRB) of our institution.

Protocols of simultaneous 18F-FDG PET/MRI

After fasting for at least 6 h, patients were injected with 0.14 mCi/kg of 18F-FDG. Serum glucose levels were obtained before 18F-FDG injection, and levels were less than 200 mg/dl in all patients. After 50 min of 18F-FDG administration, simultaneous PET/MRI scanning was performed using an integrated PET/MRI scanner (Biograph mMR, Siemens Healthcare, Erlangen, Germany). Whole-body and regional PET/MRI images were sequentially obtained, and magnetic resonance (MR) examinations were performed with a 3T MR imaging unit.

First, whole-body PET imaging was performed from the head to the distal thigh with an acquisition time of 3 min/bed and axial field of view (FoV) of 25.7 cm. Dixon-VIBE MRI was simultaneously acquired in the axial orientation to correct the PET attenuation before injection of gadolinium (Dotarem, Guerbet, France; slice thickness of 7 mm). After whole-body PET/MRI imaging was performed, the patient underwent regional PET imaging of the head and neck with an acquisition time of 10 min and regional MRI, including DWI at the same time. DWI (sequence of spin-echo echo-planar imaging (SE-EPI) with mode of strong fat saturation) was performed in the transverse plane before the contrast material injection with b values of 0 and 1000 /mm2. The pulse sequences of DWI were defined as follows: repetition time (TR) 9600 ms, echo time (TE) 93 ms, FoV 240 mm, slice thickness 4 mm, slice gap 10 mm, and voxel size 1.1 × 1.1 × 4.0 mm. None of the patients was excluded due to artifacts of the DWI sequence. Following the injection of gadolinium, a T1-weighted sequence was acquired in the axial, coronal, and sagittal directions. Axial images of regional PET and MRI were parallel to the anterior and posterior commissure line of the brain. Lutetium oxyorthosilicate (LSO)-based avalanche photodiodes were used for PET image acquisition. Images were corrected for attenuation and reconstructed on a 172 × 172 matrix using a Gaussian filter with a 6.0-mm full width at half maximum and a three-dimensional ordered-subsets expectation maximization (OSEM) algorithm (three iterations, 21 subsets, zoom of 1.0).

Image analysis of simultaneous 18F-FDG PET/MRI

All of the reviews of PET images and determination of PET parameters were performed using syngo.via software (Version VA11A; Siemens Healthcare, Erlangen, Germany) with a setting that allowed maximum intensity projection (MIP) and three-dimensional displays (transaxial, coronal, and sagittal) of PET, MRI, and fused PET/MRI images. As a first step, regional PET and diffusion-weighted MRI were fused, and we drew a large volume-of-interest (VOI) to include whole head and neck cancer. PET and MRI parameters were checked by setting isoactivity contours, and combined PET/MRI parameters were calculated (Fig. 1).
Fig. 1
Fig. 1

Measuring methods of simultaneous 18F-FDG PET/MRI parameters. As an initial step, the regional PET and ADC map were integrated. For the acquisition of PET parameters (SUVmax, MTV, and TLG), a spherical VOI (dashed red circle) was drawn to include the whole tumor. An isoactivity contour (solid blue circle) was automatically drawn by setting a threshold of SUV 2.5, and PET parameters were acquired. For an MRI parameter, a VOI was drawn along the isoactivity contour of PET, and the ADCmean of the tumor was evaluated

For the acquisition of PET parameters, the standardized uptake value (SUV) by body weight was measured for quantitative analysis according to the following equation: SUV = (tissue radioactivity (Bq)/tissue weight (g))/(total injected activity (Bq)/body weight (g)). As metabolic parameters of PET, maximum SUV (SUVmax) was measured by the highest pixel uptake. As metabolo-volumetric parameters of PET, an isoactivity contour was drawn by setting a threshold of SUV 2.5, the most frequently used threshold in previous studies [15, 16]. Metabolic tumor volume (MTV) was measured automatically by the software, and total lesion glycolysis (TLG) was calculated by multiplying SUVmean by MTV. As an MRI parameter, mean ADC (ADCmean) for head and neck cancer was measured by manually drawing a VOI on the ADC map using monoexponential ADC calcucalation method. The VOI was drawn along the isoactivity contour of PET [17, 18]. Combined PET/MRI parameters (PET parameters corrected by tumor cellularity) were calculated as the ratio between metabolic/metabolo-volumetric PET parameters and ADC. The measurement of PET and MRI parameters was done by two nuclear medicine physicians (YK and SYK; 9 and 5 years of experience) twice and averaged in blinded state to clinical data and without knowledge of histology.

Clinicopathologic parameters

Clinicopathologic parameters were obtained from a medical record review. Age, tumor site, and adjuvant therapy were checked as clinical parameters. Human papillomavirus (HPV) status, T stage, N stage, TNM stage, lymphatic invasion (lymph vessel invasion), venous invasion, and perineural invasion on surgical tumor specimen were evaluated as pathologic parameters.

Statistical analysis

Continuous parameters were expressed as mean ± standard deviation (SD), and categorical parameters were expressed as number. First, clinicopathologic and simultaneous 18F-FDG PET/MRI parameters were compared between treatment failure, and no evidence of disease groups using chi-square tests for categorical data (Mann-Whitney test for non-parametric data) and independent-samples t tests for continuous data. Second, the median values of simultaneous 18F-FDG PET/MRI parameters were identified to determine the cutoff value. Third, a Kaplan–Meier analysis and a log-rank test were done to confirm disease-free survival (DFS) and significance of simultaneous 18F-FDG PET/MRI parameters. Finally, univariate and multivariate Cox-regression analysis was performed to assess the effect of significant parameters. Bonferroni correction was done in Cox-regression analysis (univariate analysis) to counteract the problem of multiple comparisons. A log-log survival plot was used to identify the proportional hazard assumption. A P < 0.05 was considered statistically significant. All statistical analyses were performed using SPSS software (Version 18.0; SPSS Inc., Chicago, IL, USA) and MedCalc (Version 12.2; MedCalc Inc., Mariakerke, Belgium).

Results

Patients

A total of 72 patients were included in our study (M:F = 45: 27, mean age = 55.9 ± 14.6 year). Tumor locations were as follows: oral cavity and tongue 51.4%, pharynx 16.7%, larynx 8.3%, nasal cavity and paranasal sinuses 11.1%, and salivary glands 12.5%. TNM stages of the tumors were as follows: stage I = 23.6%, stage II = 19.4%, stage III = 26.4%, and stage IVA = 30.6%. Most of the patients performed neck dissection including surgery (60/72 patients, 83.3%), and rest of the patients (12/72 patients, 16.7%) performed tumorectomy due to early cancer. After surgical resection of the tumors, adjuvant therapy was done in 54.2% of patients (radiation therapy (RT) 33.3% and CCRT 20.9%), and mean follow-up was 32.8 ± 10.8 months. Twenty-two patients (30.6%) demonstrated treatment failure (confirmed 16 patients by histopathology, 6 patients by radiology), and mean treatment failure was 13.0 ± 7.0 months after surgery (Table 1).
Table 1

Baseline characteristics of patients

Characteristics

Values

Number of patients

72

Gender

M:F = 45: 27

Age (year)

55.9 ± 14.6 (range = 20–86)

Tumor site

R:L = 32: 40

Tumor location

 Oral cavity and tongue

37 (51.4%)

 Pharynx

12 (16.7%)

 Larynx

6 (8.3%)

 Nasal cavity and paranasal sinuses

8 (11.1%)

 Salivary glands

9 (12.5%)

HPV status

 Positive

10 (13.9%)

 Negative

21 (29.2%)

 N/A

41 (57.7%)

Follow-up after surgery (months)

32.8 ± 10.8 (range = 12–55)

Recurrence

22 (30.6%)

Recurrence after surgery (months)

13.0 ± 7.0 (range = 5–33)

Type of treatment failure

 Loco-regional recurrence

10 (13.9%)

 Distant metastasis

12 (16.7%)

T stage

 T1/T2

24 (33.3%)/23 (31.9%)

 T3/T4a

20 (27.8%)/5 (7.0%)

N stage

 N0

42 (58.3%)

 N1/N2

12 (16.7%)/18 (25.0%)

TNM stage

 I/II

17 (23.6%)/14 (19.4%)

 III/IVA

19 (26.4%)/22 (30.6%)

Adjuvant therapy

 No

33 (45.8%)

 RT/CCRT

24 (33.3%)/15 (20.9%)

HPV human papillomavirus, RT radiation therapy, CCRT concurrent chemoradiation therapy, N/A not assessed

Clinicopathologic parameters and treatment failure

Among the clinicopathologic parameters, T stage (P = 0.019), lymphatic invasion (P = 0.005), venous invasion (P = 0.012), and perineural invasion (P = 0.008) demonstrated significant results between treatment failure and no evidence of disease groups. However, age, tumor site, HPV status, N stage, TNM stage, and adjuvant therapy revealed no significant results (Table 2).
Table 2

Comparison of clinicopathologic parameters according to head and neck cancer treatment failure after surgery

Parameters

Treatment failure (n = 22)

No evidence of disease (n = 50)

P value

Age (year)

55.7 ± 16.0

56.0 ± 14.1

0.947

Tumor site (R:L)

8:14

24:26

0.360

HPV status

  

0.381

 Positive

4

6

 

 Negative

4

17

 

T stage

  

0.019*

 1/2

10

37

 

 3/4

12

13

 

N stage

  

0.341

 0

11

31

 

 1/2

11

19

 

TNM stage

  

0.201

 I/II

7

24

 

 III/IVA

15

26

 

Lymphatic invasion

  

0.005*

 No

11

41

 

 Yes

11

9

 

Venous invasion

  

0.012*

 No

16

47

 

 Yes

6

3

 

Perineural invasion

  

0.008*

 No

12

42

 

 Yes

10

8

 

Adjuvant therapy

  

0.113

 No

7

26

 

 RT/CCRT

15

24

 

*Statistically significant (P < 0.05)

Simultaneous 18F-FDG PET/MRI parameters and treatment failure

Among the simultaneous 18F-FDG PET/MRI parameters, MTV (P = 0.049), MTV/ADCmean (P = 0.018), and TLG/ADCmean (P = 0.025) revealed significance between treatment failure and no evidence of disease groups. However, SUVmax, TLG, ADCmean, and SUVmax/ADCmean showed no significant results (Table 3). In addition, no significant differences were found between loco-regional recurrence and distant metastasis groups (Additional file 1: Table S1).
Table 3

Comparison of 18F-FDG PET/MRI parameters according to head and neck cancer treatment failure after surgery

18F-FDG PET/MRI parameters

Treatment failure (n = 22)

No evidence of disease (n = 50)

P value

PET parameters

 SUVmax

9.7 ± 3.9

9.7 ± 5.0

0.582

 MTV

13.5 ± 13.3

7.5 ± 7.9

0.049*

 TLG

71.8 ± 81.5

40.2 ± 52.6

0.057

MRI parameters

 ADCmean

827.3 ± 232.7

972.1 ± 365.1

0.074

Combined PET/MRI parameters

 (SUVmax/ADCmean) × 1000

12.8 ± 6.0

11.3 ± 6.7

0.208

 (MTV/ADCmean) × 1000

17.8 ± 20.1

7.6 ± 7.3

0.018*

 (TLG/ADCmean) × 1000

91.1 ± 102.9

40.0 ± 48.6

0.025*

SUVmax maximum standardized uptake value, MTV metabolic tumor volume, TLG total lesion glycolysis, ADCmean mean apparent diffusion coefficient

*Statistically significant (P < 0.05)

Univariate and multivariate analysis

The univariate analysis of significant clinicopathologic parameters revealed that lymphatic invasion (P = 0.044) and perineural invasion (P = 0.046) were significant parameters. Among the 18F-FDG PET/MRI parameters, MTV (P = 0.044), MTV/ADCmean (P = 0.022), and TLG/ADCmean (P = 0.044) revealed significance after Bonferroni correction. No statistical significance was found in T stage, venous invasion, SUVmax, ADCmean, and SUVmax/ADCmean (Table 4 and Fig. 2).
Table 4

Univariate analysis with clinicopathologic and 18F-FDG PET/MRI parameters

Parameters

Hazards ratio (95% CI)

P value

Corrected P value†

T stage (3/4a vs. 1/2)

2.61 (1.12–6.05)

0.026*

0.286

Lymphatic invasion (yes vs. no)

3.40 (1.47–7.85)

0.004*

0.044*

Venous invasion (yes vs. no)

3.21 (1.26–8.22)

0.015*

0.165

Perineural invasion (yes vs. no)

3.34 (1.44–7.76)

0.004*

0.044*

SUVmax (> 5.14 vs. ≤ 5.14)

2.13 (0.96–3.03)

0.055

0.605

MTV (> 11.08 vs. ≤ 11.08)

3.48 (1.50–8.05)

0.004*

0.044*

TLG (> 59.33 vs. ≤ 59.33)

2.86 (1.23–6.63)

0.014*

0.154

ADCmean (< 1054.0 vs. ≥ 1054.0)

2.02 (1.15–4.68)

0.024*

0.264

(SUVmax/ADCmean) × 1000 (> 13.9 vs. ≤ 13.9)

2.43 (1.04–5.71)

0.041*

0.451

(MTV/ADCmean) × 1000 (> 10.8 vs. ≤ 10.8)

3.82 (1.63–8.94)

0.002*

0.022*

(TLG/ADCmean) × 1000 (> 108.9 vs. ≤ 108.9)

3.76 (1.52–9.25)

0.004*

0.044*

*Statistically significant (P < 0.05). †Multiple comparison correction by Bonferroni

Fig. 2
Fig. 2

Kaplan–Meier analysis of 18F-FDG PET/MRI parameters for prediction of tumor treatment failure after head and neck cancer surgery. DFS and P values were as follows: a SUVmax (3-year DFS = 93.8 vs. 60.1%, P = 0.055), b MTV (3-year DFS = 79.8 vs. 40.4%, P = 0.004), c TLG (3-year DFS = 76.8 vs. 40.8%, P = 0.014), d ADCmean (3-year DFS = 93.8 vs. 57.3%, P = 0.024), e MTV/ADCmean (3-year DFS = 81.1 vs. 39.5%, P = 0.002), and f TLG/ADCmean (3-year DFS = 74.4 vs. 22.7%; P = 0.004)

In the multivariate analyses, MTV, MTV/ADCmean, and TLG/ADCmean were each evaluated with significant clinicopathologic parameters (lymphatic invasion and perineural invasion). MTV (hazard ratio (HR) = 3.06, P = 0.010), MTV/ADCmean (HR = 3.12, P = 0.011), and TLG/ADCmean (HR = 4.33, P = 0.002) demonstrated significant results with lymphatic invasion (P = 0.026, 0.026, and 0.044, respectively) (Table 5 and Figs. 3 and 4).
Table 5

Multivariate analysis with significant clinicopathologic and 18F-PET/MRI parameters

Parameters

Model with MTV

Model with MTV/ADCmean

Model with TLG/ADCmean

Hazards ratio (95% CI)

P value

Hazards ratio (95% CI)

P value

Hazards ratio (95% CI)

P value

Lymphatic invasion (yes vs. no)

2.66 (1.13–6.27)

0.026*

2.66 (1.13–6.27)

0.026*

2.57 (1.02–6.45)

0.044*

Perineural invasion (yes vs. no)

 

NS

   

NS

MTV (> 11.08 vs. ≤ 11.08)

3.06 (1.31–7.13)

0.010*

 

N/A

 

N/A

(MTV/ADCmean) × 1000 (> 10.8 vs. ≤ 10.8)

 

N/A

3.12 (1.31–7.48)

0.011*

 

N/A

(TLG/ADCmean) × 1000 (> 108.9 vs. ≤ 108.9)

 

N/A

 

N/A

4.33 (1.72–10.87)

0.002*

NS not significant, N/A not assessed

*Statistically significant (P < 0.05)

Fig. 3
Fig. 3

Case of tongue cancer treatment failure prediction by both MTV and combined PET/MRI parameters. A 50-year-old male underwent preoperative simultaneous 18F-FDG PET/MRI due to a 3.8-cm-sized left tongue cancer. a Fusion image of regional PET with ADC map and b regional PET images showed left tongue mass with hypermetabolism (arrows). c ADC map image demonstrated left tongue mass with diffusion restriction (arrow). d Gadolinium-enhanced T1 axial image revealed mass with peripheral enhancement (arrow). SUVmax (9.73), MTV (35.02), TLG (135.18), ADCmean (424.15), (SUVmax/ADCmean) × 1000 (10.37), (MTV/ADCmean) × 1000 (82.57), and (TLG/ADCmean) × 1000 (318.70) predicted tumor treatment failure. The patient showed tumor treatment failure in pleura, multiple bones, and lymph nodes 6 months after tongue cancer surgery

Fig. 4
Fig. 4

Case of tonsillar cancer with no evidence of disease predicted by combined PET/MRI parameters but treatment failure predicted by PET parameters. A 66-year-old male underwent preoperative simultaneous 18F-FDG PET/MRI due to a 3.8-cm-sized left tonsillar cancer. a Fusion image of regional PET with ADC map and b regional PET images showed left tonsillar mass with hypermetabolism (arrows). c ADC map image demonstrated left tonsillar mass with diffusion restriction (arrow). d Gadolinium-enhanced T1 axial image revealed mass with peripheral enhancement (arrow). ADCmean (1443.85), (SUVmax/ADCmean) × 1000 (10.37), (MTV/ADCmean) × 1000 (10.69), and (TLG/ADCmean) × 1000 (57.53) predicted no evidence of disease; however, SUVmax (14.97), MTV (15.44), and TLG (83.07) predicted treatment failure. The patient showed no evidence of disease until 41 months follow-up after tonsillar cancer surgery

Discussion

This study demonstrated that combined PET/MRI parameters using ratio between metabolo-volumetric parameters and ADCmean can be independent prognostic factors for prediction of treatment failure in surgically resected head and neck cancer. The main advantage of our study is that we directly compared several metabolic and metabolo-volumetric parameters of PET, ADCmean of MRI, and combined PET/MRI parameters.

Among the PET parameters, SUVmax is the most commonly used parameter for quantitative analysis among the 18F-FDG PET/CT parameters, and SUVmax showed significant prognostic value in head and neck cancer [19]. In another study, SUVmean was suggested as a significant prognostic factor in head and neck cancer [20]. However, evaluation using metabolic parameters remains controversial, as tumor heterogeneity, the partial volume effect, time of SUV evaluation, measurement method, and body size may hinder the exact assessment of tumor characteristics [21]. In recent years, metabolo-volumetric parameters (MTV and TLG) have been considered more effective than metabolic parameters because tumor burden is considered by using the metabolo-volumetric parameters [22]. Previous direct comparison studies using metabolic and metabolo-volumetric parameters insisted that metabolo-volumetric parameters are superior to metabolic parameters in the prediction of head and neck cancer [23, 24]. In addition, ADC of MRI parameters also has prognostic value and reflects tumor cellularity. A previous study reported that ADC was a good prognostic factor for DFS in nasopharyngeal cancer [25]. In another direct comparison study with 18F-FDG PET/CT, ADC showed a potential to predict DFS in head and neck cancer similar to that of SUVmax [26].

PET parameters and ADC of MRI have complementary values. A study using SUV of 18F-FDG PET/CT and ADC of MRI demonstrated prognostic value in the head and neck squamous cell carcinoma separately and showed better risk stratification by combining SUV and ADC parameters [27]. However, as the modalities were different and the measurement of SUV and ADC was performed in a different manner, this study could not exactly show the direct comparison results. Recently, simultaneous 18F-FDG PET/MRI has been studied for head and neck cancer. A study showed that SUV and ADC of simultaneous 18F-FDG PET/MRI yield excellent results for detection of head and neck cancer recurrence [28]. This study showed the possibility of direct comparison between SUV and ADC parameters and their complementary values; however, metabolo-volumetric parameters of PET were not assessed. Another study using 18F-FDG PET/MRI revealed no significant correlation with metabolic parameters and ADC by direct comparison in head and neck cancer [29]. However, this study proved that each parameter was correlated with Ki-67 and nucleic area and that combined parameters (ratio between metabolic parameter and ADC) were correlated with nucleic area. We adopted this combined parameters method (named combined PET/MRI parameters (ratio between PET parameters and ADC)) in our study and evaluated its prognostic value. However, drawing VOI for ADC evaluation was another problem due to the lack of anatomical information caused by the suppressed signal in many normal tissues in DWI [11]. We adopted a PET-assisted ADC method, which showed significant predictive value in breast cancer unlike conventional ADC methods [30]. We hypothesized that as our combined PET/MRI parameters using the ratio between metabolo-volumetric parameter and ADC reflects metabolic activity, tumor burden and cellularity, they could show better prognostic value than each PET or MRI parameter.

Among the many clinicopathologic parameters, lymphatic invasion (lymph vessel invasion) was selected as a significant prognostic parameter in our study. Tumor lymphangiogenesis is a major component of metastatic process [31], and lymphatic invasion is thought to be a first step in the development of lymph node metastasis [32]. Previous studies lymphatic invasion indicates risk of lymph node metastasis and recurrence, thereby contributing to prognosis, in head and neck cancer [32, 33] and colorectal cancer [34].

Our study has some limitations. First, the HPV status of the patients showed no significant results on prognosis, which maybe due to small number of known HPV status. As many previous studies insisted that HPV status is an important factor for prognosis [35] and could affect the SUV [36] and ADC [37] measurements, it needs to be further studied with combined PET/MRI parameters in the future. In addition, SUV threshold for metabolo-volumetric parameters (MTV and TLG) is not clearly defined yet [38]. Moreover, the contoured ADC maps may not be entirely representative of the tumor as we did not contour ADC maps separately. Lastly, the diversity of adjuvant treatments could have confounded the results. A large-scale prospective study on the prognostic value of simultaneous 18F-FDG PET/MRI should be performed to confirm our results.

Conclusions

In conclusion, combined PET/MRI parameters (PET metabolo-volumetric parameters corrected by tumor cellularity) on simultaneous 18F-FDG PET/MRI could be a possible predictor of treatment failure in surgically resected head and neck cancer. In addition, MTV of PET and lymphatic invasion were other independent prognostic parameters. We expect that simultaneous 18F-FDG PET/MRI with our combined PET/MRI parameters could become a prognostic imaging modality in head and neck cancer.

Abbreviations

ADC: 

Apparent diffusion coefficient

CCRT: 

Concurrent chemoradiation therapy

CEA: 

Carcinoembryonic antigen

CT: 

Computed tomography

DFS: 

Disease-free survival

DWI: 

Diffusion-weighted imaging

FDG: 

Fluorodeoxyglucose

FoV: 

Field of view

HPV: 

Human papillomavirus

LSO: 

Lutetium oxyorthosilicate

MIP: 

Maximum intensity projection

MRI: 

Magnetic resonance imaging

MTV: 

Metabolic tumor volume

OSEM: 

Ordered-subsets expectation maximization

PET: 

Positron emission tomography

RT: 

Radiation therapy

SD: 

Standard deviation

SUV: 

Standardized uptake value

TE: 

Echo time

TLG: 

Total lesion glycolysis

TR: 

Repetition time

VOI: 

Volume-of-interest

Declarations

Acknowledgements

None

Funding

This research was supported by grant of the Research Driven Hospital R&D project, funded by the CHA Bundang Medical Center (grant number BDCHA R&D 2017-018), and by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number HI14C1072).

Authors’ contributions

YK participated in the study design, performed primary image analysis, and prepared and edited the manuscript. GJC provided critical analysis of the study design and revised the manuscript. SYK gathered patients’ clinical data and revised the manuscript. JCP aided in study design, patient recruitment, and revised the manuscript. KWK aided in patient recruitment, and DSL and JKC revised the manuscript critically. All authors read and approved the final manuscript.

Ethics approval and consent to participate

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee. Informed consent was obtained from all individual participants included in the study.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors’ Affiliations

(1)
Department of Nuclear Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea
(2)
Department of Nuclear Medicine, Seoul National University Hospital, Seoul, Republic of Korea
(3)
Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
(4)
Department of Nuclear Medicine, Seoul National University College of Medicine, 101 Daehak-ro, Chongno-gu, Seoul, 03080, Korea

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30.View ArticlePubMedGoogle Scholar
  2. Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med. 2008;49:480–508.View ArticlePubMedGoogle Scholar
  3. Halfpenny W, Hain S, Biassoni L, Maisey M, Sherman J, McGurk M. FDG–PET. A possible prognostic factor in head and neck cancer. Br J Cancer. 2002;86:512–6.View ArticlePubMedPubMed CentralGoogle Scholar
  4. Sauter AW, Wehrl HF, Kolb A, Judenhofer MS, Pichler BJ. Combined PET/MRI: one step further in multimodality imaging. Trends Mol Medicine. 2010;16:508–15.View ArticleGoogle Scholar
  5. Partovi S, Kohan A, Rubbert C, Vercher-Conejero JL, Gaeta C, Yuh R, et al. Clinical oncologic applications of PET/MRI: a new horizon. Am J Nucl Med Mol Imaging. 2014;4:202–12.PubMedPubMed CentralGoogle Scholar
  6. Pace L, Nicolai E, Aiello M, Catalano OA, Salvatore M. Whole-body PET/MRI in oncology: current status and clinical applications. Clin Transl Imaging. 2013;1:31–44.View ArticleGoogle Scholar
  7. Jadvar H, Colletti PM. Competitive advantage of PET/MRI. Eur J Radiol. 2014;83:84–94.View ArticlePubMedGoogle Scholar
  8. Lee SJ, Seo HJ, Cheon GJ, Kim JH, Kim EE, Kang KW, et al. Usefulness of integrated PET/MRI in head and neck cancer: a preliminary study. Nucl Med Mol Imaging. 2014;48:98–105.View ArticlePubMedGoogle Scholar
  9. Queiroz MA, Huellner MW. PET/MR in cancers of the head and neck. Semin Nucl Med. 2015;45:248–65.View ArticlePubMedGoogle Scholar
  10. Yamauchi H, Srinivasan A. Diffusion imaging of the head and neck. Curr Radiol Rep. 2014;2:49.View ArticleGoogle Scholar
  11. Becker M, Zaidi H. Imaging in head and neck squamous cell carcinoma: the potential role of PET/MRI. Br J Radiol. 2014;87:20130677.View ArticlePubMedPubMed CentralGoogle Scholar
  12. Zhang S-C, Bao Y-Y, Zhou S-H, Shang D-S. Application value of diffusion weighted magnetic resonance imaging in head and neck cancer. Int J Clin Exp Med. 2016;9:16747–52.Google Scholar
  13. Srinivasan A, Dvorak R, Perni K, Rohrer S, Mukherji S. Differentiation of benign and malignant pathology in the head and neck using 3T apparent diffusion coefficient values: early experience. AJNR Am J Neuroradiol. 2008;29:40–4.View ArticlePubMedGoogle Scholar
  14. King AD, Thoeny HC. Functional MRI for the prediction of treatment response in head and neck squamous cell carcinoma: potential and limitations. Cancer Imaging. 2016;16:23.View ArticlePubMedPubMed CentralGoogle Scholar
  15. Chung MK, Jeong HS, Park SG, Jang JY, Son YI, Choi JY, et al. Metabolic tumor volume of [18F]-fluorodeoxyglucose positron emission tomography/computed tomography predicts short-term outcome to radiotherapy with or without chemotherapy in pharyngeal cancer. Clin Cancer Res. 2009;15:5861–8.View ArticlePubMedGoogle Scholar
  16. Kao CH, Lin SC, Hsieh TC, Yen KY, Yang SN, Wang YC, et al. Use of pretreatment metabolic tumour volumes to predict the outcome of pharyngeal cancer treated by definitive radiotherapy. Eur J Nucl Med Mol Imaging. 2012;39:1297–305.View ArticlePubMedGoogle Scholar
  17. Brandmaier P, Purz S, Bremicker K, Höckel M, Barthel H, Kluge R, et al. Simultaneous [18F]FDG-PET/MRI: correlation of apparent diffusion coefficient (ADC) and standardized uptake value (SUV) in primary and recurrent cervical cancer. PLoS One. 2015;10:e0141684.View ArticlePubMedPubMed CentralGoogle Scholar
  18. Hoang JK, Choudhury KR, Chang J, Craciunescu OI, Yoo DS, Brizel DM. Diffusion-weighted imaging for head and neck squamous cell carcinoma: quantifying repeatability to understand early treatment-induced change. AJR Am J Roentgenol. 2014;203:1104–8.View ArticlePubMedGoogle Scholar
  19. Machtay M, Natwa M, Andrel J, Hyslop T, Anne PR, Lavarino J, et al. Pretreatment FDG-PET standardized uptake value as a prognostic factor for outcome in head and neck cancer. Head Neck. 2009;31:195–201.View ArticlePubMedGoogle Scholar
  20. Higgins KA, Hoang JK, Roach MC, Chino J, Yoo DS, Turkington TG, et al. Analysis of pretreatment FDG-PET SUV parameters in head-and-neck cancer: tumor SUV mean has superior prognostic value. Int J Radiat Oncol Biol Phys. 2012;82:548–53.View ArticlePubMedGoogle Scholar
  21. Thie JA. Understanding the standardized uptake value, its methods, and implications for usage. J Nucl Med. 2004;45:1431–4.PubMedGoogle Scholar
  22. Y-i K, Paeng JC, Cheon GJ, Suh K-S, Lee DS, Chung J-K, et al. Prediction of posttransplantation recurrence of hepatocellular carcinoma using metabolic and volumetric indices of 18F-FDG PET/CT. J Nucl Med. 2016;57:1045–51.View ArticleGoogle Scholar
  23. Lim R, Eaton A, Lee NY, Setton J, Ohri N, Rao S, et al. 18F-FDG PET/CT metabolic tumor volume and total lesion glycolysis predict outcome in oropharyngeal squamous cell carcinoma. J Nucl Med. 2012;53:1506–13.View ArticlePubMedGoogle Scholar
  24. Choi K-H, Yoo IR, Han EJ, Kim YS, Kim GW, Na SJ, et al. Prognostic value of metabolic tumor volume measured by 18F-FDG PET/CT in locally advanced head and neck squamous cell carcinomas treated by surgery. Nucl Med Mol Imaging. 2011;45:43–51.View ArticlePubMedGoogle Scholar
  25. Zhang Y, Liu X, Zhang Y, Li W-F, Chen L, Mao Y-P, et al. Prognostic value of the primary lesion apparent diffusion coefficient (ADC) in nasopharyngeal carcinoma: a retrospective study of 541 cases. Sci Rep. 2015;5:12242.View ArticlePubMedPubMed CentralGoogle Scholar
  26. Nakajo M, Nakajo M, Kajiya Y, Tani A, Kamiyama T, Yonekura R, et al. FDG PET/CT and diffusion-weighted imaging of head and neck squamous cell carcinoma: comparison of prognostic significance between primary tumor standardized uptake value and apparent diffusion coefficient. Clin Nucl Med. 2012;37:475–80.View ArticlePubMedGoogle Scholar
  27. Preda L, Conte G. Combining standardized uptake value of FDG-PET and apparent diffusion coefficient of DW-MRI improves risk stratification in head and neck squamous cell carcinoma. Eur Radiol. 2016;26:4432–41.View ArticlePubMedGoogle Scholar
  28. Becker M, Varoquaux AD, Combescure C, Rager O, Pusztaszeri M, Burkhardt K, et al. Local recurrence of squamous cell carcinoma of the head and neck after radio(chemo)therapy: diagnostic performance of FDG-PET/MRI with diffusion-weighted sequences. Eur Radiol. 2017; https://doi.org/10.1007/s00330-017-4999-1.
  29. Surov A, Stumpp P, Meyer HJ, Gawlitza M, Höhn A-K, Boehm A, et al. Simultaneous 18F-FDG-PET/MRI: associations between diffusion, glucose metabolism and histopathological parameters in patients with head and neck squamous cell carcinoma. Oral Oncol. 2016;58:14–20.View ArticlePubMedGoogle Scholar
  30. Byun BH, Noh WC, Lim I, Lee SS, Cho AR, Park JA, et al. A new method for apparent diffusion coefficient measurement using sequential 18F-FDG PET and MRI: correlation with histological grade of invasive ductal carcinoma of the breast. Ann Nucl Med. 2013;27:720–8.View ArticlePubMedGoogle Scholar
  31. Stacker SA, Baldwin ME, Achen MG. The role of tumor lymphangiogenesis in metastatic spread. FASEB J. 2002;16:922–34.View ArticlePubMedGoogle Scholar
  32. Michikawa C, Uzawa N, Kayamori K, Sonoda I, Ohyama Y, Okada N, et al. Clinical significance of lymphatic and blood vessel invasion in oral tongue squamous cell carcinomas. Oral Oncol. 2012;48:320–4.View ArticlePubMedGoogle Scholar
  33. Longatto Filho A, Oliveira TG, Pinheiro C, de Carvalho MB, Curioni OA, Mercante AM, et al. How useful is the assessment of lymphatic vascular density in oral carcinoma prognosis? World J Surg Oncol. 2007;5:140.View ArticlePubMedPubMed CentralGoogle Scholar
  34. Liang P, Nakada I, Hong JW, Tabuchi T, Motohashi G, Takemura A, et al. Prognostic significance of immunohistochemically detected blood and lymphatic vessel invasion in colorectal carcinoma: its impact on prognosis. Ann Surg Oncology. 2007;14:470–7.View ArticleGoogle Scholar
  35. Dayyani F, Etzel CJ, Liu M, Ho CH, Lippman SM, Tsao AS. Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC). Head Neck Oncol. 2010;2:15.View ArticlePubMedPubMed CentralGoogle Scholar
  36. Sharma SJ, Wittekindt C, Knuth J, Steiner D, Wuerdemann N, Laur M, et al. Intraindividual homogeneity of (18)F-FDG PET/CT parameters in HPV-positive OPSCC. Oral Oncol. 2017;73:166–71.View ArticlePubMedGoogle Scholar
  37. de Perrot T, Lenoir V. Apparent diffusion coefficient histograms of human papillomavirus-positive and human papillomavirus-negative head and neck squamous cell carcinoma: assessment of tumor heterogeneity and comparison with histopathology. AJNR Am J Neuroradiol. 2017;38:2153–60.View ArticlePubMedGoogle Scholar
  38. Pak K, Cheon GJ, Nam HY, Kim SJ, Kang KW, Chung JK, et al. Prognostic value of metabolic tumor volume and total lesion glycolysis in head and neck cancer: a systematic review and meta-analysis. J Nucl Med. 2014;55:884–90.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2018

Advertisement